Detalles de la búsqueda
1.
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Lancet HIV
; 11(2): e75-e85, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38141637
2.
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.
Lancet Infect Dis
; 19(3): 253-264, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30732940
Resultados
1 -
2
de 2
1
Próxima >
>>